8-K: Travere Reports Strong Q4 2025 Sales, FILSPARI Growth

Travere Therapeutics announced robust fourth quarter and full year 2025 financial results, driven by significant growth in FILSPARI sales and progress in its rare disease pipeline.

Summary

• U.S. net product sales for the fourth quarter of 2025 were $126.6 million, a significant increase from $73.5 million in the same period of 2024.
• For the full year 2025, U.S. net product sales reached $410.5 million, up from $226.7 million in 2024.
• FILSPARI U.S. net product sales totaled $103.3 million in Q4 2025, representing 108% growth year-over-year, and $322.0 million for the full year 2025, a 144% growth.
• The company received an all-time high of 908 new patient start forms (PSFs) for FILSPARI during the fourth quarter.
• Net income for Q4 2025 was $2.7 million, or $0.03 per basic share, a substantial improvement from a net loss of $60.3 million in Q4 2024.
• The full year 2025 net loss was $25.5 million, or $0.29 per basic share, significantly reduced from a $321.5 million net loss in 2024.
• On a non-GAAP adjusted basis, net income for Q4 2025 was $33.3 million ($0.37 per basic share) and for the full year 2025 was $81.1 million ($0.91 per basic share).
• Cash, cash equivalents, and marketable securities stood at $322.8 million as of December 31, 2025.
• The PDUFA target action date for FILSPARI in Focal Segmental Glomerulosclerosis (FSGS) is April 13, 2026.
• Enrollment activities have resumed for the pivotal Phase 3 HARMONY Study of pegtibatinase in classical Homocystinuria (HCU).

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a very positive report, demonstrating strong commercial execution, significant financial improvement, and promising pipeline advancements, particularly with FILSPARI's growth and the upcoming FSGS PDUFA date.

Positives

• U.S. net product sales increased by 72.2% in Q4 2025 and 81.1% for the full year 2025 compared to prior periods.
• FILSPARI sales demonstrated robust growth of 108% in Q4 2025 and 144% for the full year 2025.
• An all-time high of 908 new patient start forms for FILSPARI were received in Q4 2025, indicating strong market adoption.
• The company achieved a GAAP net income of $2.7 million in Q4 2025, a significant turnaround from a $60.3 million net loss in Q4 2024.
• Full year 2025 GAAP net loss was substantially reduced to $25.5 million from $321.5 million in 2024.
• Non-GAAP adjusted net income for the full year 2025 was $81.1 million, a major improvement from a $241.0 million non-GAAP net loss in 2024.
• A strong cash position of $322.8 million in cash, cash equivalents, and marketable securities as of December 31, 2025.
• Anticipated receipt of a $25 million sales-based milestone payment from Mirum Pharmaceuticals in the first half of 2026.
• Progress towards potential FDA approval for FILSPARI in FSGS with a PDUFA target action date of April 13, 2026.
• Resumption of enrollment activities for the pivotal Phase 3 HARMONY Study of pegtibatinase in classical HCU, a potential first-in-class disease-modifying therapy.
• International expansion of FILSPARI by partners, with Chugai Pharmaceutical expecting to submit an NDA in Japan in 2026 and CSL Limited having launched in several European countries.

Negatives

• Selling, general, and administrative (SG&A) expenses increased significantly to $101.7 million in Q4 2025 (from $69.5 million in Q4 2024) and to $337.2 million for the full year 2025 (from $264.1 million in 2024), primarily due to preparations for a potential FSGS launch and increased commercialization investment for FILSPARI in IgAN.
• The company still reported a GAAP net loss for the full year 2025, despite significant improvement.

Risks

• There is no guarantee that the FDA will grant approval of FILSPARI for FSGS on the anticipated timeline, or at all.
• Risks and uncertainties are associated with the company's business and finances in general, and the success of its commercial products.
• Risks and uncertainties are associated with its preclinical and clinical stage pipeline.
• Risks and uncertainties are associated with the regulatory review and approval process.
• Risks and uncertainties are associated with enrollment of clinical trials for rare diseases.
• Ongoing or planned clinical trials may not succeed or may be delayed for safety, regulatory, or other reasons.
• Risks are associated with the ongoing commercial launch of FILSPARI in IgAN.
• Market acceptance of commercial products, including efficacy, safety, price, reimbursement, and benefit over competing therapies, is not guaranteed.
• Risks are related to the challenges of manufacturing scale-up.
• Risks are associated with the successful development and execution of commercial strategies for products, including FILSPARI.
• Risks are related to potential disruptions to clinical trials, commercialization activity, supply chain, and manufacturing operations due to global and macroeconomic conditions, including health epidemics and pandemics.
• The company may be unable to raise additional funding that may be required to complete development of any or all of its product candidates, potentially as a result of macroeconomic conditions.
• Dependence on contractors for clinical drug supply and commercial manufacturing poses risks.
• Uncertainties relate to patent protection and exclusivity periods and intellectual property rights of third parties.
• Risks are associated with regulatory interactions.
• Risks and uncertainties relate to competitive products, including current and potential future generic competition, and technological changes that may limit demand for the company's products.

Future Outlook

The company is positioned for a successful commercial launch of FILSPARI in FSGS, if approved by the April 13, 2026 PDUFA date. It expects to continue generating clinical evidence to support FILSPARI's role as a foundational therapy in IgAN and is progressing the Phase 3 HARMONY Study of pegtibatinase in classical HCU. Travere anticipates receiving a $25 million sales-based milestone payment in the first half of 2026 and potential milestone/royalty payments from international partners, including Chugai Pharmaceutical's expected NDA submission for sparsentan in Japan in 2026.

Management Comments

• "2025 marked a year of meaningful advancement for Travere, strengthening both our commercial execution and long-term growth outlook."
• "In IgA nephropathy, continued adoption of FILSPARI underscores its foundational positioning and the positive impact we are delivering for patients and physicians."
• "At the same time, we are extending our leadership across rare kidney and metabolic diseases by finalizing preparations for a potential launch in FSGS and progressing the Phase 3 HARMONY Study of pegtibatinase in classical HCU."
• "Together, these efforts enhance our potential to reach more patients in the near term while reinforcing a trajectory for sustainable, long-term growth."

Industry Context

StockSavvy.ai notes that Travere Therapeutics is solidifying its position in the rare kidney and metabolic disease space, particularly with the strong performance of FILSPARI in IgAN and the anticipated expansion into FSGS. The resumption of the HARMONY study for pegtibatinase positions the company to potentially introduce a first-in-class disease-modifying therapy for HCU, addressing significant unmet needs in these specialized markets and reinforcing its leadership in orphan drug development.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct comparison to industry standards.

Stakeholder Impact

• Shareholders: Positive impact due to strong sales growth, improved financial performance (net income in Q4, reduced net loss for FY), and pipeline progress, potentially leading to increased share value.
• Patients: Positive impact through continued adoption of FILSPARI for IgAN, potential approval for FSGS, and progress in developing pegtibatinase for HCU, offering new or improved treatment options for rare diseases.
• Employees: Positive impact from company growth and pipeline advancements, potentially leading to job security and opportunities.
• Partners (Chugai, CSL, Mirum): Positive impact through successful commercialization and regulatory progress of shared assets, leading to potential milestone and royalty payments.

Next Steps

• FDA review of the supplemental New Drug Application (sNDA) for FILSPARI in FSGS, with a PDUFA target action date of April 13, 2026.
• Finalizing preparations for a successful commercial launch of FILSPARI in FSGS, if approved.
• Continuing enrollment activities for the pivotal Phase 3 HARMONY Study of pegtibatinase in classical HCU.
• Generating clinical evidence to support FILSPARI's role as foundational therapy in IgAN through ongoing and planned studies and presentations at key medical meetings.
• Chugai Pharmaceutical expects to submit a New Drug Application for sparsentan in Japan in 2026.
• Expected receipt of a $25 million sales-based milestone payment from Mirum Pharmaceuticals in the first half of 2026.

Key Dates

Recommendation

The company demonstrated exceptional commercial execution with FILSPARI, achieving significant sales growth and a substantial improvement in profitability, moving from a large net loss to net income in Q4 and drastically reducing its full-year loss. The upcoming PDUFA date for FSGS and the resumed Phase 3 study for pegtibatinase represent major catalysts for future growth and market expansion in rare diseases, indicating strong underlying business momentum and potential for continued value creation.

Keywords

Travere Therapeutics, TVTX, FILSPARI, sparsentan, IgA nephropathy, IgAN, Focal Segmental Glomerulosclerosis, FSGS, pegtibatinase, classical Homocystinuria, HCU, rare kidney disease, rare metabolic disease, financial results, Q4 2025, full year 2025, PDUFA, clinical trials, biopharmaceutical, drug development, patient start forms